Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Suzhou Ribo Life Science / Equity Capital Markets

<ul>
<li>RiboLife raised HKD 1832m (USD 236m) from its global offering and will list on the Hong Kong Stock Exchange on Friday January 9th, 2026.</li>
<li>In our previous note, we looked at the company's fundamentals and the valuation.</li>
<li>In this note, we provide an update for the IPO before its trading debut.</li>
</ul>


RiboLife raised HKD 1832m (USD 236m) from its global offering and will list on the Hong Kong Stock Exchange on Friday January 9th, 2026.
In our previous note, we looked at the company's fundamentals and the valuation.
In this note, we provide an update for the IPO before its trading debut.


HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<ul>
<li>For the first time, price negotiation has been included in commercial insurance catalog in 2025 NRDL negotiations, which will have a significant leverage effect on domestic R&amp;D/commercialization of innovative drugs.</li>
<li>In the next decade, China will become the most core region for global biopharmaceutical innovation. Chinese pharmaceutical companies are also expected to emerge as true global biotech companies.</li>
<li>Based on Ribo’s IPO pricing (HK$57.97/share) and 2024 revenue, P/S is 59x, which is lower than peer.This valuation/IPO pricing is not without basis, with potential room for future valuation increases.</li>
</ul>


For the first time, price negotiation has been included in commercial insurance catalog in 2025 NRDL negotiations, which will have a significant leverage effect on domestic R&amp;D/commercialization of innovative drugs.
In the next decade, China will become the most core region for global biopharmaceutical innovation. Chinese pharmaceutical companies are also expected to emerge as true global biotech companies.
Based on Ribo’s IPO pricing (HK$57.97/share) and 2024 revenue, P/S is 59x, which is lower than peer.This valuation/IPO pricing is not without basis, with potential room for future valuation increases.


China Healthcare Weekly (Jan.4) - NRDL Negotiation Breakthrough, Thoughts on Ribo's IPO Pricing

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>Ribo Life Sciences launched its Hongkong IPO aiming to raise up to HK$1,593.4M. The company plans to sell 27.5M shares at HK$57.97 per share.</li>
<li>Ribo Life Sciences is a biopharmaceutical company engaged in oligonucleotide research and development, with a focus on siRNA therapeutics.</li>
<li>Growth outlook does not quite justify the premium valuation of the company. We think the Ribo Life Science issue is slightly over priced. Investors can avoid the issue for now.</li>
</ul>


Ribo Life Sciences launched its Hongkong IPO aiming to raise up to HK$1,593.4M. The company plans to sell 27.5M shares at HK$57.97 per share.
Ribo Life Sciences is a biopharmaceutical company engaged in oligonucleotide research and development, with a focus on siRNA therapeutics.
Growth outlook does not quite justify the premium valuation of the company. We think the Ribo Life Science issue is slightly over priced. Investors can avoid the issue for now.


Ribo Life IPO: SiRNA Story Good, Issue Seems Slightly Overpriced Considering the Long Waiting Game

<ul>
<li>Suzhou Ribo Life, a China-based siRNA therapeutics company, launched its IPO to raise at least USD 206 million via a Hong Kong listing.</li>
<li>In this note, we look at the deal terms and provide a valuation for the company.</li>
<li>We think the risk-reward is not attractive for the deal.</li>
</ul>


Suzhou Ribo Life, a China-based siRNA therapeutics company, launched its IPO to raise at least USD 206 million via a Hong Kong listing.
In this note, we look at the deal terms and provide a valuation for the company.
We think the risk-reward is not attractive for the deal.


RiboLife-B (瑞博生物) IPO:  High Price Tag

<ul>
<li>Suzhou Ribo Life is looking to raise at least US$100 million via a Hong Kong listing. CICC and Citi are the deal sponsors.</li>
<li>While our previous notes cover the fundamentals of the company, in this note we look at the updates from the latest PHIP prospectus.</li>
<li>We think the company is still worth following as it streamlines its product pipeline and makes progress in clinical trials.</li>
</ul>


Suzhou Ribo Life is looking to raise at least US$100 million via a Hong Kong listing. CICC and Citi are the deal sponsors.
While our previous notes cover the fundamentals of the company, in this note we look at the updates from the latest PHIP prospectus.
We think the company is still worth following as it streamlines its product pipeline and makes progress in clinical trials.


Suzhou Ribo Life Science (瑞博生物) Pre-IPO: PHIP Updates Highlight Asset Prioritization

China

Develops siRNA therapeutics for liver, cardiovascular, metabolic and renal diseases

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Suzhou Ribo Life Science (6938 HK)

RiboLife-B (瑞博生物) IPO Trading

RiboLife to list on HKEX after raising USD 236m in global offering. In this note, we provide an update on the trading dynamics prior to its...

Ke Yan, CFA, FRM

China Healthcare Weekly (Jan.4) - NRDL Negotiation Breakthrough, Thoughts on Ribo's IPO Pricing

China's inclusion of price negotiation in of commercial insurance will boost R&D,making it a core region for biotech innovation.Ribo's IPO pricing...

Xinyao (Criss) Wang

Ribo Life IPO: SiRNA Story Good, Issue Seems Slightly Overpriced Considering the Long Waiting Game

Ribo Life Sciences launches Hong Kong IPO, aiming to raise HK$1,593.4M with focus on siRNA therapeutics, but growth outlook may not justify...

Tina Banerjee

RiboLife-B (瑞博生物) IPO: High Price Tag

China's siRNA therapeutics company Suzhou Ribo Life launches IPO in Hong Kong to raise at least $206 million. We look at the deal terms and...

Ke Yan, CFA, FRM

Suzhou Ribo Life Science (瑞博生物) Pre-IPO: PHIP Updates Highlight Asset Prioritization

Ribo Life Sciences is looking to raise USD100m via a Hong Kong listing. As the company filed the post hearing prospectus, we look at changes in...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

RiboLife-B (瑞博生物) IPO Trading

​RiboLife to list on HKEX after raising USD 236m in global offering. In this note, we provide an update on the trading dynamics prior to its...

Ke Yan, CFA, FRM

China Healthcare Weekly (Jan.4) - NRDL Negotiation Breakthrough, Thoughts on Ribo's IPO Pricing

​China's inclusion of price negotiation in of commercial insurance will boost R&D,making it a core region for biotech innovation.Ribo's IPO pricing...

Xinyao (Criss) Wang

Ribo Life IPO: SiRNA Story Good, Issue Seems Slightly Overpriced Considering the Long Waiting Game

​Ribo Life Sciences launches Hong Kong IPO, aiming to raise HK$1,593.4M with focus on siRNA therapeutics, but growth outlook may not justify...

Tina Banerjee

RiboLife-B (瑞博生物) IPO: High Price Tag

​China's siRNA therapeutics company Suzhou Ribo Life launches IPO in Hong Kong to raise at least $206 million. We look at the deal terms and...

Ke Yan, CFA, FRM

Suzhou Ribo Life Science (瑞博生物) Pre-IPO: PHIP Updates Highlight Asset Prioritization

Ribo Life Sciences is looking to raise USD100m via a Hong Kong listing. As the company filed the post hearing prospectus, we look at changes in...

Ke Yan, CFA, FRM

RiboLife to list on HKEX after raising USD 236m in global offering. In this note, we provide an update on the trading dynamics prior to its...

China's inclusion of price negotiation in of commercial insurance will boost R&D,making it a core region for biotech innovation.Ribo's IPO pricing...

Ribo Life Sciences launches Hong Kong IPO, aiming to raise HK$1,593.4M with focus on siRNA therapeutics, but growth outlook may not justify...

China's siRNA therapeutics company Suzhou Ribo Life launches IPO in Hong Kong to raise at least $206 million. We look at the deal terms and...